The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.

Immune-Onc Therapeutics, a US-based immuno-oncology therapy developer drawing on research from University of Texas, announced on Tuesday it has secured $73m in series B1 and B2 funding. Investment management firm Oceanpine Capital led the round and was joined by Octagon Capital, Sphera Healthcare, Northern Light Venture Capital, Vivo Capital and Leukemia & Lymphoma Society’s Therapy…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.